@ClearNoteHealth profile picture
ClearNote Health @ClearNoteHealth

Cancer detection company enabling people at risk for high-mortality cancers to live longer healthier lives. Learn more at our website ⬇️ #biotechnology

Joined September 2018
  • Tweets 60
  • Following 57
  • Followers 162
38 Photos and videos
Pinned Tweet
ClearNote Health@ClearNoteHealth
28 Apr 2025
This account is no longer actively managed. Please follow all our activity on the following channels or visit our website: clearnotehealth.com/ linkedin.com/company/clearno… bsky.app/profile/clearnotehe… Thank you!
47
ClearNote Health’s Avantect® Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for @theNCI’s Vanguard Study. Read the PR: clearnotehealth.com/press-re…
1
57
Did you know that Type 2 Diabetes can increase the risk of pancreatic as well as other cancers? Recently, Dr. Steve Edelman and the Taking Control Of Your Diabetes (@TCOYD) team highlighted the connection between #diabetes and #pancreaticcancer: tcoyd.org/2024/09/the-connec…
1
1
85
Avantect Ovarian Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services Learn more: clearnotehealth.com/press-re…
0:16
78
📢 ClearNote Health will be at the 14th World CB & CDx Boston Summit, Sept 3rd-6th. 📍Find us at #Booth35 and learn more about the advantages of the Virtuoso Epigenomics Platform for longitudinal analysis in your translational research. #drugdevelopment #therapyresponse
1
37
Join us at #TRICON as Samuel Levy, Chief Scientific Officer, shares how unlocking the full potential of #epigenomics will improve #cancer patient care through early detection: lnkd.in/ggXA78z4
187
We look forward to presenting @ASCO #GI23. Join @ClearNote Health poster session on Jan,20, 12:00 - 1:30 PM and 4:30-5:30 PM to learn about early detection of #PancreaticCancer using 5hmC-based #liquidbiopsy (abstract 672)
2
217
We look forward to providing an update on our progress with the Avantect Pancreatic Cancer Detection Test at #jpm23. Join Dave Mullarkey, CEO, today at 2:30 p.m. PST at the Westin St Francis, Mission Bay room #pancreaticcancer #precisionmedicine #earlydetection
0:06
3
382
Join Dave Mullarkey, CEO, at #JPM23 for a discussion on our ongoing clinical validation efforts and the commercialization roadmap for The Avantect™ Early #cancer Detection Portfolio. clearnotehealth.com/press-re…
3
573
#NEWS: Bluestar Genomics is now ClearNote Health. Our name has changed, but our goal remains the same – developing non-invasive tests to detect #cancer earlier than existing methods by harnessing the power of #epigenomics. clearnotehealth.com/press-re… #genomics #precisionmedicine
0:35
2
4
475
Today we announced the initiation of one of the largest #PancreaticCancer studies to date using epigenomic approach to enable #earlydetection. Learn more: bluestargenomics.com/press-r…
1
4
Did you know that #diabetes and #PancreaticCancer are linked? Learn more from @diabetesdaily: diabetesdaily.com/blog/there…
1
Join us tomorrow for a presentation by @Samuel Levy, Bluestar Genomics Chief Science Officer, at @The Lustgarten Foundation's webinar focused on innovation in early detection of #PancreaticCancer. Register now: lnkd.in/d5rUCKF8 #genomics #cancer #EarlyDetection
2
Our Chief Science Officer, Samuel Levy, PhD, is presenting at @Lustgarten webinar about #innovation in #earlydetection of #PancreaticCancer Join us on Nov. 16 x.com/lustgartenfdn/status/1…

Lustgarten Foundation@lustgartenfdn
31 Oct 2022
Join us on November 16 for "LustgartenLIVE! The Intersection of Science and Technology: Advancing Patient Care." Save your spot for this engaging webinar today! #LedByLustgarten lustgarten.org/live
1
3
#Immunotherapy can help #lung cancer patients. But, not all patients will respond to the treatment. During #SITC22, on Nov. 10, we present study results demonstrating - for the first time - the potential of 5hmC to predict and monitor Tx effectiveness. lnkd.in/g9n_duc8
1
We are pleased to mark #Movember2022 with @CR_AACR publication on our research with @UCSFCancer collaborator Dr. Felix Feng to extend understanding on non-invasive diagnosis and monitoring of #ProstateCancer : aacrjournals.org/cancerres/a…

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer

In prostate cancer, 5-hydroxymethylcytosine delineates oncogene activation and stage-specific cell states and can be analyzed in liquid biopsies to detect cancer phenotypes.

aacrjournals.org
2
1
Anna Bergamaschi, PhD, presented positive results from the validation study of the Pancreatic Cancer Detection Test at #APA22. To learn more about the Bluestar Genomics test availability, visit: lnkd.in/gauvNTtS #genomics #cancer #liquidbiopsy
0:20
3
Today we announced positive results from a validation study for our early pancreatic #cancer detection test and launched a physician experience program to bring the test into clinical use. Learn more about presentation at #APA22: tinyurl.com/3ndpa9n5 #genomics #EarlyDetection
0:19
1
5
Bluestar Genomics receives CAP. “This a testament to our focus on preparing the company to serve customers around the world, helping millions of patients avoid late-stage, untreatable cancer diagnosis,” said David Mullarkey, CEO. tinyurl.com/2zvk77jh #liquidbiopsy #genomics
5
New Data at #ESMO22, #AACRPan22, #AGBTPH highlight the expansion of the company's platform, underscoring the feasibility of widespread deployment of 5hmC-based #epigenomics technology for early detection of #cancer & understanding resistance to treatments. businesswire.com/news/home/2…

Bluestar Genomics Presents Data on New Applications of its Epigenomic Cancer Detection Platform

Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy tests initially foc...

businesswire.com
1
5
Load more